Lodewyk F A Wessels
Overview
Explore the profile of Lodewyk F A Wessels including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
179
Citations
10445
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bakker N, Garner H, van Dyk E, Champanhet E, Klaver C, Duijst M, et al.
NPJ Breast Cancer
. 2025 Jan;
11(1):5.
PMID: 39843922
Cancer disrupts intratumoral innate-adaptive immune crosstalk, but how the systemic immune landscape evolves during breast cancer progression remains unclear. We profiled circulating immune cells in stage I-III and stage IV...
2.
Nederlof I, Isaeva O, de Graaf M, Gielen R, Bakker N, Rolfes A, et al.
Nat Med
. 2024 Sep;
30(11):3223-3235.
PMID: 39284953
Immune checkpoint inhibition (ICI) with chemotherapy is now the standard of care for stage II-III triple-negative breast cancer; however, it is largely unknown for which patients ICI without chemotherapy could...
3.
Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial
Opdam M, van Rossum A, Hoogstraat M, Bounova G, Horlings H, van Werkhoven E, et al.
iScience
. 2024 Aug;
27(8):110425.
PMID: 39206149
The primary objective of the prospective, randomized, multicenter, phase 3 biomarker Microarray Analysis in breast cancer to Taylor Adjuvant Drugs Or Regimens trial (MATADOR: ISRCTN61893718) is to generate a gene...
4.
Vis D, Jaaks P, Aben N, Coker E, Barthorpe S, Beck A, et al.
Cell Rep Med
. 2024 Aug;
5(8):101687.
PMID: 39168097
Combining drugs can enhance their clinical efficacy, but the number of possible combinations and inter-tumor heterogeneity make identifying effective combinations challenging, while existing approaches often overlook clinically relevant activity. We...
5.
Chelushkin M, van Dorp J, van Wilpe S, Seignette I, Mellema J, Alkemade M, et al.
Clin Cancer Res
. 2024 Jul;
30(18):4227-4239.
PMID: 39047168
Purpose: Platinum-based chemotherapy and immune checkpoint inhibitors are key components of systemic treatment for muscle-invasive and advanced urothelial cancer. The ideal integration of these two treatment modalities remains unclear as...
6.
Zeverijn L, Geurts B, Battaglia T, van Berge Henegouwen J, de Wit G, Hoes L, et al.
Clin Cancer Res
. 2024 Jul;
30(19):4339-4351.
PMID: 39024037
Purpose: The treatment efficacy of nivolumab was evaluated in patients with advanced, treatment-refractory solid mismatch repair deficiency/microsatellite-instable (dMMR/MSI) tumors, and in-depth biomarker analyses were performed to inform precision immunotherapy approaches....
7.
Boon N, Oliveira R, Korner P, Kochavi A, Mertens S, Malka Y, et al.
Science
. 2024 May;
384(6697):785-792.
PMID: 38753784
In response to excessive DNA damage, human cells can activate p53 to induce apoptosis. Cells lacking p53 can still undergo apoptosis upon DNA damage, yet the responsible pathways are unknown....
8.
Geurts B, Zeverijn L, Leek L, van Berge Henegouwen J, Hoes L, van der Wijngaart H, et al.
Clin Cancer Res
. 2024 Apr;
30(17):3735-3746.
PMID: 38630551
Purpose: To evaluate the efficacy of pembrolizumab across multiple cancer types harboring different levels of whole-genome sequencing-based tumor mutational load (TML; total of nonsynonymous mutations across the genome) in patients...
9.
Gil-Jimenez A, van Dijk N, Vos J, Lubeck Y, van Montfoort M, Peters D, et al.
Nat Commun
. 2024 Mar;
15(1):2538.
PMID: 38514623
Immune checkpoint inhibitors (ICI) can achieve remarkable responses in urothelial cancer (UC), which may depend on tumor microenvironment (TME) characteristics. However, the relationship between the TME, usually characterized by immune...
10.
Gaillard D, Lof P, Sistermans E, Mokveld T, Horlings H, Mom C, et al.
Int J Gynecol Cancer
. 2024 Feb;
34(5):713-721.
PMID: 38388177
Objective: To assess the feasibility of scalable, objective, and minimally invasive liquid biopsy-derived biomarkers such as cell-free DNA copy number profiles, human epididymis protein 4 (HE4), and cancer antigen 125...